NASDAQ:PIRS Pieris Pharmaceuticals (PIRS) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free PIRS Stock Alerts $11.06 -0.02 (-0.18%) (As of 05/6/2024 ET) Add Compare Share Share Today's Range$10.80▼$11.4150-Day Range$11.06▼$17.2452-Week Range$10.60▼$80.80Volume17,029 shsAverage Volume24,184 shsMarket Capitalization$13.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pieris Pharmaceuticals alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Pieris Pharmaceuticals Stock (NASDAQ:PIRS)Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Read More PIRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PIRS Stock News HeadlinesMay 7, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)April 29, 2024 | americanbankingnews.comPieris Pharmaceuticals (NASDAQ:PIRS) Coverage Initiated at StockNews.comMay 7, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.April 1, 2024 | msn.comAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72MMarch 28, 2024 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 27, 2024 | finance.yahoo.comPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty PotentialMarch 19, 2024 | finance.yahoo.comPIRS Apr 2024 2.500 callFebruary 10, 2024 | investing.comPieris Pharmaceuticals Inc (PIRS)May 7, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.February 1, 2024 | finance.yahoo.comPieris Pharmaceuticals, Inc. (PIRS)December 18, 2023 | finance.yahoo.comInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%November 20, 2023 | investing.comPieris Pharmaceuticals Inc (PIRS) Earnings Dates & ReportsNovember 4, 2023 | morningstar.comPieris Pharmaceuticals Inc PIRSSeptember 25, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's WhyAugust 24, 2023 | finance.yahoo.comIs Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive AnalysisAugust 23, 2023 | finance.yahoo.comPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should KnowAugust 18, 2023 | msn.comPieris (PIRS) Up On Receiving Milestone Payment From PartnerAugust 17, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology BispecificJuly 19, 2023 | finance.yahoo.comPieris (PIRS) Pursues Strategic Alternatives, Stock RisesJuly 19, 2023 | markets.businessinsider.comPieris Pharma Cuts Around 70% Workforce; Plans Strategic OptionsJuly 18, 2023 | finanznachrichten.dePieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 18, 2023 | finance.yahoo.comWhy Pieris Pharmaceuticals Shares Shooting Higher Today?July 18, 2023 | finance.yahoo.comPieris Pharmaceuticals Provides Strategic Update and Announces RestructuringJuly 13, 2023 | fool.comPieris Pharmaceuticals (NASDAQ: PIRS)June 21, 2023 | msn.comWhy Are Pieris Pharmaceuticals Shares Tanking TodayJune 21, 2023 | finance.yahoo.comPieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology StudyJune 11, 2023 | finance.yahoo.comWe're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn RateSee More Headlines Receive PIRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today5/06/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PIRS CUSIPN/A CIK1583648 Webwww.pieris.com Phone(857) 246-8998Fax49-8161-141-1444Employees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($22.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,540,000.00 Net Margins-57.33% Pretax Margin-57.33% Return on Equity-90.17% Return on Assets-38.12% Debt Debt-to-Equity RatioN/A Current Ratio3.24 Quick Ratio3.24 Sales & Book Value Annual Sales$42.81 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$21.66 per share Price / Book0.51Miscellaneous Outstanding Shares1,240,000Free Float1,127,000Market Cap$13.71 million OptionableOptionable Beta0.55 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Comp: $774.72kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Comp: $499.38kMaria KelmanExecutive Director of Investor RelationsDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Mr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project LeadershipMore ExecutivesKey CompetitorsEdesa BiotechNASDAQ:EDSANanoViricidesNYSE:NNVCTonix PharmaceuticalsNASDAQ:TNXPTraws PharmaNASDAQ:TRAWVaxxinityNASDAQ:VAXXView All CompetitorsInsiders & InstitutionsSummit Trail Advisors LLCBought 140,000 shares on 4/23/2024Ownership: 0.142%Christopher P KiritsyBought 125 shares on 5/25/2023Total: $8,500.00 ($68.00/share)View All Insider TransactionsView All Institutional Transactions PIRS Stock Analysis - Frequently Asked Questions Should I buy or sell Pieris Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PIRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PIRS, but not buy additional shares or sell existing shares. View PIRS analyst ratings or view top-rated stocks. How have PIRS shares performed in 2024? Pieris Pharmaceuticals' stock was trading at $14.56 at the beginning of the year. Since then, PIRS shares have decreased by 24.0% and is now trading at $11.06. View the best growth stocks for 2024 here. Are investors shorting Pieris Pharmaceuticals? Pieris Pharmaceuticals saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 300 shares, a decrease of 99.8% from the March 31st total of 134,100 shares. Based on an average daily volume of 10,500 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company's stock are sold short. View Pieris Pharmaceuticals' Short Interest. When is Pieris Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PIRS earnings forecast. How were Pieris Pharmaceuticals' earnings last quarter? Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Friday, March, 29th. The biotechnology company reported ($4.00) EPS for the quarter. The biotechnology company had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative trailing twelve-month return on equity of 90.17%. When did Pieris Pharmaceuticals' stock split? Pieris Pharmaceuticals's stock reverse split on the morning of Tuesday, April 23rd 2024. The 1-80 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Pieris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL). Who are Pieris Pharmaceuticals' major shareholders? Pieris Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Summit Trail Advisors LLC (0.14%). Insiders that own company stock include Christopher P Kiritsy, Shane Olwill and Tim Demuth. View institutional ownership trends. How do I buy shares of Pieris Pharmaceuticals? Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PIRS) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.